Y-K. Kang

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

Jia-Lin Lee, Y-K. Kang, Hye Jin Kang et al. · British Journal of Cancer · 2008 · 136 citations · Full text

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

Narikazu Boku, M.-H. Ryu, D-Y. Oh et al. · Annals of Oncology · 2020 · 123 citations

Chemotherapy Versus Chemotherapy, Gastrointestinal Oncology, Medicine +8

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Dok Hyun Yoon, M.-H. Ryu, Y S Park et al. · British Journal of Cancer · 2012 · 87 citations · Full text

Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)

Josep Tabernero, Paulo M. Hoff, Lin Shen et al. · Annals of Oncology · 2017 · 58 citations · Full text

Her2-positive Metastatic Gastric, Gastrointestinal Oncology, Medicine +8

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

Y-K. Kang, Changhoon Yoo, B-Y. Ryoo et al. · British Journal of Cancer · 2013 · 53 citations · Full text